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Though the cause of motor abnormalities in cerebral palsy is injury to the brain, structural
changes in muscle and fascia may add to stiffness and reduced function. This study
examined whether myofascial structural integration therapy, a complementary treatment
that manipulates muscle and fascia, would improve gross motor function and gait in
children <4 years with cerebral palsy. Participants (N = 29) were enrolled in a random-
ized controlled trial (NCT01815814, https://goo.gl/TGxvwd) or Open Label Extension.
The main outcome was the Gross Motor Function Measure-66 assessed at 3-month
intervals. Gait (n = 8) was assessed using the GAITRite® electronic walkway. Parents
completed a survey at study conclusion. Comparing Treatment (n = 15) and Waitlist-
Control groups (n = 9), we found a significant main effect of time but no effect of group
or time × group interaction. The pooled sample (n = 27) showed a main effect of time,
but no significantly greater change after treatment than between other assessments.
Foot length on the affected side increased significantly after treatment, likely indicating
improvement in the children’s ability to approach a heel strike. Parent surveys indicated
satisfaction and improvements in the children’s quality of movement. MSI did not increase
the rate of motor skill development, but was associated with improvement in gait quality.
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introduction
Cerebral palsy (CP) is the term used to describe a set of non-progressive disorders of movement 
and posture that lead to limitations in functional activity and can be attributed to disturbances that 
occurred in the fetal or infant brain. These disorders of movement are frequently accompanied by 
other medical or functional issues: disturbances of sensation, perception, cognition, communica-
tion, and/or behavior; epilepsy; and/or secondary musculoskeletal problems (1). The prevalence of 
CP has been reported to be 2.11 (2) to 3.6 cases/1000 (3), making it the most common movement 
disorder of childhood. The most prevalent variant is spastic CP. Muscles affected by spasticity have 
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increased velocity-dependent sensitivity to stretch, causing stiff-
ness, tightness, and interference with movement, which can lead 
to joint contracture and deformity. Children with mild forms of 
spastic CP usually walk independently. Visual gait analysis has 
identified slower velocity, shorter stride length, and longer double 
support time in ambulatory children with CP relative to typically 
developing peers (4).
None of the common treatments for spastic CP, including 
physical and occupational therapy; bracing; medications; and 
surgical procedures is completely satisfactory. Non-invasive 
treatments often have limited or temporary treatment effects that 
fail to substantially change the natural course of the condition or 
improve an affected limb’s functional capacity (5, 6). Localized 
treatment with injections of botulinum toxin A is associated with 
only temporary improvements in selected gait parameters and 
in reducing spasticity (7–10). Systematic reviews suggest that a 
combination of approaches may be more effective than a single 
approach to treatment (11).
In the past, spasticity was attributed solely to the etiologic 
non-progressive central nervous system injury. Recent evidence 
suggests that skeletal muscle and its extracellular matrix are 
altered in CP (12, 13). Increased passive stiffness within the mus-
cle bundle is accompanied by increased collagen content within 
the extracellular matrix and by increased sarcomere length, rather 
than by abnormalities of the mechanical properties of individual 
muscle fibers. These findings implicate structural changes in the 
muscle and extracellular matrix of muscle as important con-
tributors to the increased muscle tone and stiffness in CP (14). 
Targeting the local structural changes, especially before the 
development of contractures and deformities, might, therefore, 
be a helpful component of a comprehensive strategy to improve 
motor function in young children with CP. The goal of the present 
study was to determine if a treatment that manipulated muscle 
and surrounding fascia, used as an adjunct to physical therapy, 
occupational therapy, and routine medical care, could improve 
motor function and gait in young children with spastic CP.
The treatment we assessed was myofascial structural integra-
tion (MSI). MSI is a specific manipulative and movement-based 
complementary medicine practice, developed by Dr. Ida P. Rolf 
in the 1930s. In MSI, a trained practitioner manually manipu-
lates muscle and fascia in order to free up stiff body parts and 
joints, increase stability, improve balance and mobility, and 
put the body into proper alignment to facilitate improved 
motor patterns. This treatment was selected because its goals 
are appropriate for children with CP, it follows a standard and 
reproducible 10-week protocol and it addresses the whole body, 
not just legs or arms. Previous research on MSI for individuals 
with CP found that patients with mild CP experienced improve-
ments in such gait parameters as cadence, velocity, and stride 
length after a standard course of treatment with MSI (15). A 
recent preliminary randomized crossover design trial of MSI in 
young children with CP showed greater improvements after a 
course of MSI than after a comparable number of control play 
sessions, though some children improved throughout the entire 
study (16). A case report found improvements in cadence and 
double support time in two children with spastic CP after MSI 
(17). MSI is distinct from massage, another movement-based 
complementary practice, which has been shown to have variable 
effects on adolescents with CP (18).
The primary aim of this study was to determine whether MSI 
therapy, used as an adjunct to physical and occupational therapy, 
could improve gross motor function in young children with spas-
tic CP. We hypothesized that a course of MSI treatment added to 
the existing regimen of physical and occupational therapy would 
lead to greater gains in gross motor function than the therapies 
alone. A secondary aim of the study was to evaluate changes to 
select gait parameters after the treatment in those children who 
were ambulatory at the time of Enrollment. The final aim was to 
obtain parental impressions of the MSI treatment and its impact 
on the children after treatment. Though MSI is a non-invasive 
approach, we surveyed families after the treatment to determine if 
there were any adverse effects and to learn if parents saw benefits 
that were not captured in our assessments.
If MSI were to prove effective, it could be incorporated into the 
treatment plan of young children with spastic CP as an adjunct 
to conventional therapies. Ideally, it would delay or eliminate 
the need for risky, invasive, or time-limited treatment options. 
Because it is safe, it could also be used repeatedly across the child’s 
development. It is important to prove efficacy because though 
safe, the standard course of 10 sessions may not be reimbursed 
by health insurance and is, therefore, expensive for families.
Materials and Methods
Participants
Young children with spastic CP were recruited from a university 
medical clinic, state-funded medical therapy programs that serve 
children with CP, and through self-referral from local publicity. 
We studied young children, less than age 48 months at the time 
that consent was obtained because they are in a dynamic period of 
development, generally before the onset of deformities and con-
tractures, and therefore possibly more likely to change than older 
children or adults. Eligibility criteria were as follows: diagnosis 
of spastic CP (or mixed CP with spasticity); no recent history of 
seizures, surgery, or botulinum toxin A injections; receiving physi-
cal therapy; and level II, III, or IV on the Gross Motor Function 
Classification System (GMFCS) or a level of II, III, IV on the Manual 
Ability Classification System (MACS) for children who were 
GMFCS I, as determined by a physical therapist or pediatrician 
on the study team. Throughout the study, the children continued 
to participate in their typical treatment regimen, which included 
physical therapy at minimum and depending on the child, may 
have also included occupational therapy, medications, other com-
plementary treatments (e.g., Feldenkrais Method), and regular 
recreational activities (e.g., swimming). The Institutional Review 
Board at Stanford University approved the protocol and parents 
provided informed consent prior to their child’s participation.
study Design
The study was conducted in two phases. Phase 1 was a rand-
omized controlled trial (RCT). We enrolled 26 children in the 
Randomized Cohort on a rolling basis and assigned them to 
one of the two groups through the use of a random number 
sorter: Treatment (n = 13) or Waitlist-Control Group (n = 13) 
September 2015 | Volume 3 | Article 743
Loi et al. Myofascial therapy in cerebral palsy
Frontiers in Pediatrics | www.frontiersin.org
(Figure 1). Two children, one from each group, did not complete 
the treatment protocol and were dropped from further analyses. 
Three children originally assigned to the Waitlist-Control Group 
were reassigned to the Treatment Group to accommodate the 
children’s circumstances: one to complete the treatment protocol 
before the anticipated birth of a sibling, one to avoid delay in 
physician-prescribed botulinum toxin A injections, and one to 
avoid further waiting for a child whose participation was delayed 
while she enrolled in a physical therapy program. The revised 
sample size in the Randomized Cohort was Treatment Group 
n = 15 children and Waitlist-Control Group n = 9.
Phase 2 was an Open Label Extension. Children randomized 
to the Waitlist-Control Group received the treatment after the 
wait period. In addition, funding permitted the enrollment of five 
additional children (“Non-Randomized Cohort”), all of whom 
were assigned to the Treatment Group in order to complete the 
protocol before the end of the funding period. We then compared 
the Treatment Group (n =  20) to the Waitlist-Control Group 
(n = 9). We also evaluated the pooled sample (n = 27) for change 
over time.
All of the participants were scheduled for an evaluation at 
Enrollment and every 3 months for a total participation period 
of 9 months. Figure 2 shows the stages of the study. All of the 
children waited 3 months and had a second assessment prior to 
MSI treatment in order for us to assess the rate of developmental 
change prior to the experimental treatment. The second assess-
ment was called the Pre-Treatment Assessment for the Treatment 
Group and the Wait Assessment for the Waitlist-Control Group 
(Figure  2). The Treatment Group underwent MSI therapy 
between the second and third assessments. The Waitlist-Control 
Group began MSI therapy after the third assessment. Both groups 
had a Post-Treatment Assessment and the Treatment Group 
was also assessed at a 3-month Maintenance assessment. All 
participants completed at least three assessments, including the 
post-treatment assessment, and 27 of the 29 children completed 
four assessments (one moved away from the geographic area 
before study completion and one began therapy with botulinum 
toxin A injections), to show whether skills remained stable during 
maintenance for the Treatment Group.
Treatment
Each child was scheduled for 10 weekly 60- to 90-min sessions 
of the MSI intervention. All of the children completed 9 or 10 of 
the scheduled sessions. A single Certified Advanced Rolfer (KSP) 
with over 35  years of experience working with young children 
provided the therapy in her private studio. MSI treatments fol-
lowed the specific, structured sequence that addressed the entire 
body. The researchers prepared the parents and the children by 
explaining the therapy as a type of bodywork similar to deep 
tissue massage. Children remained partially clothed and lay on 
a table, sat on the floor, or sat on a parent’s lap during the treat-
ment. During each session, the clinician manually manipulated 
the muscles and fascia of the section of the body that was the 
focus for that day.
Primary Outcome Measure: The gross Motor 
Function Measure-66
An assessor (physical therapist or pediatrician) blind to each 
child’s group assignment completed the Gross Motor Function 
Measure-66 (GMFM-66). The GMFM-66 is an observational 
measure that was developed to capture the gross motor capacity 
of children with CP. It is has been shown to be valid, reliable, and 
responsive to change (19). The 66-item tool utilizes a 0–3 rating 
scale to measure skills in five different dimensions (A: Lying and 
FigUre 1 | study group assignment: original randomization group assignments in the randomized cohort, subsequent shifts, and addition of the 
non-randomized cohort.
FigUre 2 | study design: assessment points and treatment periods for the Treatment and Waitlist-control groups.
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Rolling, B: Sitting, C: Crawling and Kneeling, D: Standing, and E: 
Walking, Running, and Jumping). The total score, between 0 and 
100 (higher scores indicating greater function), is obtained using 
specialized program scoring software that is based on a logit scale. 
Each assessment was videotaped and scored. After the conclusion 
of the study, videos for participants who demonstrated irregular 
score patterns were reviewed and their corresponding GMFMs 
rescored if required.
secondary Outcome Measure: gaiTrite® 
electronic Walkway
Gait assessments of all ambulatory children were recorded and 
analyzed using the GAITRite® electronic walkway. Its ease of 
operation makes this 14-foot walkway suitable for use with 
children. Several studies have documented the reliability of 
the measures in children with CP (20–22). As a child traverses 
the GAITRite® walkway, pressure exerted by foot contact on the 
surface activates sensor pads embedded in the electronic mat. The 
walkway records the geometry of the activating foot contact and 
the relative arrangement of contact points in two-dimensional 
space. Spatial and temporal characteristics of the gait are calcu-
lated based on foot contact geometry.
Children walked barefoot over the walkway at a self-selected 
pace. Multiple passes over the walkway were obtained at each 
assessment. For analysis, a Walk was defined as the averaged 
data of the first two and up to four passes over the walkway that 
included a minimum of eight fluent steps in one direction across 
the mat with one foot always on the mat (indicating a walking 
pace). Passes in which the participants ran, stopped, or navigated 
off the mat were excluded.
secondary Outcome Measure: Parent 
satisfaction survey
At the conclusion of the study, parents were given a “Parent 
Satisfaction Survey” that the research team developed to record 
parents’ impressions of changes they saw in their children over 
the course of the study. The survey also allowed parents to 
provide feedback to the researchers about the study in general. 
The survey included the domains of emotional affect, functional 
body control, balance/flexibility, strength, height, weight, and 
functional achievements. The 11-question survey included open-
response questions, such as, “Did you notice any changes in your 
child’s balance/flexibility (walking, standing, climbing stairs, trip-
ping)?” and “Did you notice any changes in your child’s strength 
(self support, pulling up, climbing)?” The survey also included 
two ratings of satisfaction: “Parent Rating of Satisfaction” and 
“Parent Rating of Child Satisfaction.” Each rating was recorded 
on a Likert Scale, with 1 as the lowest score and 10 as the highest 
score.
Data analysis
Primary Analysis
Analyses were conducted using SPSS version 22. As preliminary 
analyses, we first compared the Treatment and Waitlist-Control 
groups from the Randomized Cohort using independent-samples 
t-tests and Fisher’s Exact Test to establish if the groups were com-
parable on the basis of mean age, gender, race (comparing White 
to Non-White), CP type (comparing hemiparesis diagnosis to 
non-hemiparesis diagnosis), CP severity (comparing GMFCS 
levels I and II to III and IV), and mean GMFM-66 score at 
Enrollment. To assess treatment efficacy within the Randomized 
Cohort, we used a Repeated Measures ANOVA; GMFM scores 
at assessments II and III (Pre-Treatment to Post-Treatment for 
the Treatment Group and Wait Assessment to Pre-Treatment for 
the Waitlist-Control Group) were the within subject variables and 
randomization group was the between subject variable.
In the Open Label Extension, we compared the five children 
in the Non-Randomized Cohort to the group of 24 children in 
the Randomized Cohort using independent-samples t-tests and 
Fisher’s Exact Test to ensure that the groups remained compa-
rable in composition on the same metrics as mentioned above. 
We then compared the expanded Treatment Group (n = 20) to 
the Waitlist-Control Group (n =  9) using Repeated Measures 
ANOVA, following the same strategy as in the RCT.
In order to examine whether there were time by group interac-
tions at any point during the study, we completed the Repeated 
Measures ANOVA on the pooled sample of children who com-
pleted all four assessments (n =  27). For this analysis, GMFM 
TaBle 1 | Demographic and clinical information on participants.
randomized 
cohort
non-randomized 
cohort
Waitlist-
control (n = 9)
Treatmenta 
(n = 15)
Treatmentb 
(n = 5)
Mean age, years (SD) 2.2 (0.8) 2.4 (1.0) 2.1 (0.7)
Male, % (n) 55.6 (5) 40.0 (6) 20.0 (1)
Non-White, % (n) 44.4 (4) 26.7 (4) 60.0 (3)
Type of spastic 
cerebral palsy, % (n)
Hemiparesis: 
44.4 (4)
Hemiparesis: 
33.3 (5)
Hemiparesis: 
60.0 (3)
Diplegia: 0.0 (0) Diplegia: 20.0 (3) Diplegia: 0.0 (0)
Quadriparesis: 
55.6 (5)
Quadriparesis: 
46.7 (7)
Quadriparesis: 
40.0 (2)
Gross Motor 
Function 
Classification System 
level, % (n)
Level 1: 11.1 (1) Level 1: 20.0 (3) Level 1: 40.0 (2)
Manual ability Manual ability Manual ability
Classification Classification Classification
System System System
Level 2: n = 0 Level 2: n = 1 Level 2: n = 0
Level 3: n = 1 Level 3: n = 2 Level 3: n = 1
Level 4: n = 0 Level 4: n = 0 Level 4: n = 1
Level 2: 33.3 (3) Level 2: 26.7 (4) Level 2: 20.0 (1)
Level 3: 0.0 (0) Level 3: 20.0 (3) Level 3: 0.0 (0)
Level 4: 55.6 (5) Level 4: 33.3 (5) Level 4: 40.0 (2)
Mean Gross Motor 
Function Measure-66 
score at Enrollment 
(SD)
37.9 (19.8) 40.6 (14.7) 40.3 (17.7)
aDifferences between Waitlist-Control and Treatment groups within the Randomized 
Cohort were not statistically different.
bDifferences between the Randomized and Non-Randomized cohorts were not 
statistically different.
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scores at assessments I–IV were the within group variable and 
randomization group was the between group variable.
secondary analyses
For the secondary gait analysis, we selected a small set of depend-
ent variables that captured different aspects of gait from the many 
inter-related measures that the GAITRite® walkway generates, as 
follows: foot length and foot width, derived from the length and 
width of sensors activated by foot pressure progressing along the 
mat, and stride length, defined as the forward-progressing line 
between the heel points of two consecutive footprints of the same 
foot. Selected temporal parameters were as follows: double sup-
port time, defined as the percent of the gait cycle spent with both 
feet on the mat, and velocity, defined as distance traveled divided 
by ambulation time (23). Paired samples t-tests were performed to 
compare Pre-Treatment to Post-Treatment measurements. When 
differences were noted, paired t-tests were used to determine if 
differences were present between the assessment immediately 
prior to the Pre-Treatment Assessment (Enrollment for the 
Treatment Group and Wait Assessment for the Waitlist-Control 
Group) and Pre-Treatment and also between Post-Treatment and 
Maintenance Assessments.
For the Parent Satisfaction Survey, the mean scores for the two 
Likert scales of “Parent Rating of Satisfaction” and “Parent Rating 
of Child Satisfaction” were calculated from all available responses.
results
randomized controlled Trial
Table  1 shows demographic and clinical characteristics of 
the children in the RCT. Within the Randomized Cohort, the 
Treatment Group (n = 15) did not differ from the Waitlist-Control 
Group (n = 9) in terms of mean age, gender, race, CP type, CP 
severity as measured by the GMFCS, and mean GMFM-66 score 
at Enrollment.
The critical assessment of the efficacy of MSI treatment was 
change in GMFM scores between assessments II and III. There 
was a significant effect of time F(1, 22) = 8.096, p = 0.009, but 
no significant effect of group F(1, 22) = 0.394, p = 0.537 and no 
significant time by group interaction F(1, 22) = 0.911, p = 0.350.
Open label extension
Table 1 documents that the five additional participants who con-
stituted the Non-Randomized Cohort did not differ significantly 
from the group of randomized participants in terms of mean age, 
gender, race, CP type, severity of CP as measured by the GMFCS, 
and mean GMFM-66 score at Enrollment.
With the larger sample (N = 29), the comparison of change 
in scores for the Treatment Group and for the Waitlist-Control 
Group from assessment II to III found a main effect of time F(1, 
27) = 9.786, p = 0.004 but no effect of group F(1, 27) = 0.435, 
p = 0.515 or time by group interaction F(1, 27) = 1.349, p = 0.256. 
Figure  3 shows the estimated marginal mean scores for the 
GMFM assessments at the two time points.
The pooled sample that underwent four assessments (n = 27) 
was used to detect any differences in rate of change between the 
two groups from Enrollment to the final assessment. Mauchly’s 
Test indicated that the assumption of sphericity had been violated 
for the main effects of time, x2(5) = 23.458, p = 0.000. Thus, we 
used the Greenhouse–Geisser correction for degrees of freedom 
(ϵ  =  0.615). There was a significant effect of time, F(1.845, 
46.114) = 18.324, p = 0.000, but no significant effect of group, F(1, 
25) = 0.090, p = 0.767 and no time by group interaction, F(1.845, 
46.114) = 0.866, p = 0.420. Figure 4 shows the change across the 
four assessments for the two groups in the pooled sample.
secondary results: gait Parameters
Table  2 includes the mean values for the Pre-Treatment and 
Post-Treatment Assessments for each measure in comparison 
to normative data for children of comparable ages on those 
measures (22, 24). Two spatial parameters, foot width and stride 
length, and both temporal parameters were unchanged before 
and after treatment.
Foot length on the more affected side increased significantly 
for the pooled sample between the Pre-Treatment and Post-
Treatment intervals (M =  12.1, SD =  2.03) and (M =  12.59, 
SD = 2.32), p = 0.04. Figure 5 shows foot length of the more affected 
foot in study participants over time, with normative foot size for 
children in this age group referenced (24). Subsequent analyses 
found that foot length did not change between the assessment 
prior to Pre-Treatment (Enrollment for the Treatment Group and 
Wait Assessment for the Waitlist-Control Group) and the Pre-
Treatment Assessment (M = 12.04, SD = 2.23) and (M = 12.1, 
SD  =  2.03), p  =  0.76 and were maintained at Maintenance 
FigUre 4 | estimated marginal means on gross Motor Function 
Measure-66 (gMFM-66) from assessments i through iV for the pooled 
sample. (Assessment I is the Enrollment Assessment for both groups. 
Assessment II is the Pre-Treatment Assessment for the Treatment Group and 
the Wait Assessment for the Waitlist-Control Group. Assessment III is the 
Post-Treatment Assessment for the Treatment Group and the Pre-Treatment 
Assessment for the Waitlist-Control Group. Assessment IV is the 
Maintenance Assessment for the Treatment Group and the Post-Treatment 
Assessment for the Waitlist-Control Group.)
FigUre 3 | estimated marginal means on the gross Motor Function 
Measure-66 (gMFM-66) from assessment ii to assessment iii for the 
pooled sample. (Assessment II is the Pre-Treatment Assessment for the 
Treatment Group and the Wait Assessment for the Waitlist-Control Group. 
Assessment III is the Post-Treatment Assessment for the Treatment Group 
and the Pre-Treatment Assessment for the Waitlist-Control Group.)
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(M = 12.8, SD = 2.35), p = 0.40. As shown in Figure 5, the effect 
was greatest in the children with hemiplegia; the change between 
Pre-Treatment and Post-Treatment for these seven children was 
significant (M = 11.86, SD = 2.06) and (M = 12.46, SD = 2.48), 
p = 0.02.
secondary results: Parent satisfaction survey
Parents of 25 of the 29 participants (86%) completed the Parent 
Survey. The mean “Parent Rating of Satisfaction” was high at 
8.4/10 (minimum  =  3.0, maximum  =  10.0, SD  =  1.9). The 
“Parent Rating of Child Satisfaction” was high at 8.6/10.0 (mini-
mum = 3.0, maximum = 10.0, SD = 1.8).
Many parents reported observed qualitative improvements in 
their children’s gross motor skills. One parent wrote that her child 
experienced “improved walking, climbing stairs, sitting on floor 
cross-legged, decreased limp.” Another parent noticed that her 
child held his “left hand less fisted.” A common comment was 
that the children enjoyed the massage. One parent said, “It felt 
so good to him like massage.” Another exclaimed, “Rolfing – she 
loved it! And we saw many gains during therapy.” Changes were 
also noted in subjective well-being and quality of life, such as 
“improved mood.” One parent reported that her child had a 
“more relaxed demeanor[,] improved sleep[, and was] calmer 
for longer periods of time.” Another parent concluded her 
survey by writing, “We will do it again in the future.”
TaBle 2 | Mean gait parameters on more affected side in relation to 
normative data for ambulatory children with cP.
Parameter normative 
data mean 
(sD)
Pre-
Treatment 
mean (sD)
Post-
Treatment 
mean (sD)
t p
Foot length (cm) 16.0 (2.52) 12.1 (2.03) 12.6 (2.32) −2.54 0.04
Foot width (cm) 7.0 (2.11) 5.8 (1.33) 6.1 (1.48) −0.98 0.36
Stride length (cm) 68.8 (14.55) 62.8 (6.52) 64.1 (7.68) −0.50 0.63
Double support 
time (% gait cycle)
16.5 (5.0) 21.9 (4.40) 20.1 (5.24) 0.95 0.38
Velocity (cm/s) 101.1 (29.9) 84.1 (11.40) 86.6 (14.51) −0.47 0.65
Discussion
summary of results
The aim of this study was to investigate the effect of MSI therapy 
on the gross motor function and gait of young children with CP. 
The results of both the RCT and Open Label Extension showed 
that the children improved in gross motor function over time, 
but the rate of improvement on this measure was no greater 
immediately after treatment than with developmental change 
alone. Analyses of spatial and temporal gait parameters using 
FigUre 5 | Foot length on the more affected side of ambulatory participants with cP.
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an electronic walkway revealed changes in foot length, possibly 
representing improved heel strike, on the more affected side but 
no changes in the other gait parameters. A parent survey at the 
conclusion of the study found that parents were generally very 
satisfied with the treatment and saw improvements in their chil-
dren’s function that were not detected by the selected outcomes 
measures. In summary, in this sample of children with CP, MSI 
did not increase the rate of motor skill development, but was 
associated with an improvement in gait quality and with positive 
parent reports of changes.
lack of change in gMFM-66 scores as a 
Function of Treatment
We did not detect changes in the rate of improvement on the 
GMFM as the result of MSI treatment. These negative findings 
suggest that MSI treatment is not effective in improving the rate 
of gross motor development in children with CP. However, the 
secondary analyses suggested modest qualitative improvements. 
It is, thus, possible that the treatment led to changes that were not 
detected by the GMFM-66 measure.
The GMFM is a very demanding outcome measure. Studies of 
other therapies have also failed to reach significant change on the 
broader 88-item GMFM measure (25). Studies assessing botuli-
num toxin A injections have found improvements in spasticity 
reduction and gait improvements without corresponding statistical 
difference in GMFM scores between treatment and control groups 
(26–29), did not include a control group, or did not compare the 
GMFM improvement to that expected with time alone (30, 31). 
Of over 100 studies, we found only three RCT studies that showed 
improvements in GMFM scores after treatment with botulinum 
toxin A compared to controls (32–35). For future studies, other 
outcomes measures of gross motor skill that may be more sensitive 
to change than the GMFM-66 should be considered.
Why might the GMFM fail to register change as a result of 
therapy in our study population? The assessment requires coop-
eration from the children during testing. Young children with 
CP may be inconsistent in their behavior and motivation and, 
therefore, inconsistent in their performance on the measure. In 
this study, most children showed consistent improvement in their 
GMFM-66 score. However, occasionally, children experienced a 
reduction in their scores from session to session. Many factors, 
such as mood, sleep disturbance, and level of cooperation, may 
contribute to the variability in scores (36). For children who are 
either at the floor or the ceiling of the skills that the GMFM is 
able to measure, a very slight change in consistency in the child’s 
performance may bring about a dip in performance.
Another challenge in using the GMFM-66 as the outcome 
measure is that the degree of expected change varies as a function 
of age and severity of motor disability. In previous trials, children 
who were young (<3 years of age) and had mild CP showed greater 
change in GMFM scores than children who were older and had 
more severe CP (19). Because the children in our study were 
young, the rate of developmental change, even without treatment, 
was relatively rapid, making it difficult to discern changes specifi-
cally related to the intervention. An acknowledged limitation of 
the GMFM measure is that children functioning in the middle of 
the GMFM-66 range have greater potential to change than chil-
dren whose initial assessment is either very low or very high. In 
this study, 6 children were at GMFCS Level I and 12 children were 
GMFCS Level IV, with 18 out of 29 total participants in either 
of one of these categories. In both of these groups, it would be 
difficult to detect change based on the treatment. Because of the 
heterogeneity of the etiology and clinical presentation amongst 
children with a diagnosis of CP, Damiano recently cautioned that 
in order to advance evidence-based practice in the field of CP 
treatment, investigators and clinicians must consider each child 
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individually when determining a treatment’s potential to improve 
function, and when developing and interpreting RCTs, answering 
not only the question of “what works” but also the question of 
“what works for whom” (37).
A final challenge in using the GMFM-66 as the outcome 
measure was that it was designed to measure change in skill 
level rather than change in quality of movements. As stated by 
Russell in a validation study for an early version of the GMFM, 
“It is likely that the changes detected by the GMFM reflect only 
part of the ‘real’ change in motor behavior over time, since many 
aspects of improvement are qualitative rather than quantitative. 
For example, we have the impression that when children use aids 
to perform motor functions they often have more qualitative 
than quantitative improvement in function. The GMFM does not 
appear to detect these changes or improvement well” (38). Indeed, 
in order to achieve a higher score on the GMFM-66, children 
must make relatively major changes in gross motor function. For 
example, a child with hemiplegia may have a markedly improved 
heel strike after treatment, contributing to stability and balance. 
To observe changes on the GMFM-66, however, she might have 
to make the significant gain of being able to stand on her affected 
leg and kick a ball with her other foot. Such an accomplishment 
might exceed the type of change that the improved heel strike 
might be expected to induce.
changes in the gait analyses after Treatment
The quasi-experimental gait analysis demonstrated a sig-
nificant increase in foot length on the more affected side after 
treatment. We interpreted increased foot length as an increase 
in the amount of foot contact with the mat. We did not think 
that the change represented growth in the foot because the 
less affected foot did not change significantly in length and 
both feet did not change in width, as would be predicted with 
growth. Rather, the selective increase in foot length most likely 
represents a lowering of the heel toward the floor and decreased 
toe walking, resulting in greater overall foot contact with the 
mat. We do not think that this finding was a spurious result. 
We did not find a change in foot length prior to treatment, 
in the maintenance phase, or in the foot on the less affected 
side. Improvements in heel strike could be seen visually on the 
videotapes obtained during the use of the GAITRite® electronic 
walkway. Finally, some parents mentioned on the final survey 
that they had observed an improvement in gait and balance. It 
is also interesting to note that three children began to walk dur-
ing or shortly after MSI. One child started walking within a few 
months of completing the treatment. These data suggest that 
MSI, when used as a complementary treatment, may improve 
aspects of gait in ambulatory children with mild spastic CP.
Ambulatory children with spastic CP demonstrate specific gait 
abnormalities. Ankle plantar flexor muscles are often overactive 
with ineffective dorsiflexor muscles, leading to the dynamic equinus 
foot deformity and poor heel strike, or incomplete foot contact, 
characteristic of toe walking. Decrease in dynamic equinus can 
be a treatment goal because it contributes to balance, stability, and 
reduces energy expenditures during walking, leading to functional 
improvements. The change in foot length occurred despite the 
fact that MSI treatment encompassed the whole body and did not 
specifically address only the foot. Targeting a specific part of the body 
may not be necessary for change to occur. It is interesting to note that 
this improvement in a motor skill would not be quantified in the 
GMFM-66, supporting the notion that MSI may improve quality 
of movement rather than promote quantitative functional change.
Two previous studies of MSI and gait found improvements in 
gait that we did not detect. A 10-child case series using bilateral 
insole sensors to assess gait parameters found that children with 
mild CP demonstrated improvements in cadence, velocity, and 
stride length; children with moderate CP demonstrated only 
improvements in velocity; and ambulatory children with severe 
CP did not demonstrate any gait improvements (15). Because of 
our small sample size, we did not analyze our ambulatory children 
separately based on CP severity, and, therefore, we may not have 
picked up on any differences within individual severity subgroups 
as the earlier study did. A recent case series using similar method-
ology as the current study in two older children with spastic CP 
found improvements in cadence and double support time after a 
course of MSI (17). Unlike the previous study, we analyzed only 
passes over the mat in which one foot was on the mat at all times in 
order to eliminate runs. Velocity independently influences cadence 
and time spent in single support and double support for children 
with CP (39). We chose to limit gait measurement variability by 
eliminating runs. However, we may have limited our ability to 
detect increases in maximum velocity, and its correlate, cadence. 
Likewise, because a running child is likely to spend less time in 
double support than a walking child, we may have been less likely 
to find changes for this gait parameter in our walking sample.
results of the Parent survey
The qualitative reports from parents of the participants suggested 
that the children benefited from the therapy in ways not quanti-
fied by the Gross Motor Function Measure-66. Parent comments 
included “better walking, balance still shaky but better,” “better 
head control,” “improved functional use of hands,” and “decreased 
limp.” Such comments highlighted improvements in the quality 
of the children’s movements rather than in motor skills that would 
be measured by the GMFM-66. Such qualitative changes may 
contribute to the children’s ability to engage in day-to-day tasks. 
We recognize that parents were aware of which treatment phase 
the child was in over the course of participation in the study.
limitations
Limitations of the study were the relatively small sample size of 29 
children and the uneven distribution of GMFCS levels. In addi-
tion, the Treatment and Control groups were weighted toward 
more severe levels of CP, which may have limited the amount 
of improvement we were able to observe with the GMFM-66. 
Furthermore, because of scheduling conflicts and the late addi-
tion of five participants into the Treatment Group without ran-
domization, our Treatment Group and Waitlist-Control Group 
were unequal in size, although similar in other variables. In the 
secondary gait analysis, because of the small study sample size, 
there were not enough ambulatory participants to utilize the RCT 
design of the larger study for the analyses, so a quasi-experimental 
design was used. We did not have any measures of motor function 
other than the GMFM-66, which is not a sensitive measure for 
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detecting improvements in quality of movement. Similarly, the 
GAITRite® electronic walkway may not be the optimal modality 
for determining improved heel strike or other gait improve-
ments; metrics reflecting ankle kinetics, kinematics and use of 
in-shoe foot sensor technology might yield greater precision and 
accuracy. We did not have any measures that assessed spasticity 
reduction in our children. Another limitation is that the young 
participants were inconsistent in their performance on the 
GMFM assessments and in their gait assessments. We reported 
inconsistent performances on the GMFM assessments for some 
children and eliminated many passes across the GAITRite® mat 
because of erratic ambulation. This variability and these exclu-
sions may have limited our ability to observe changes.
conclusion and Future Directions
In summary, MSI treatment used as a complementary treatment 
in young children with spastic CP did not increase the children’s 
rates of change on the GMFM-66 beyond the background rate of 
change from development and other therapeutic interventions. In 
ambulatory children, the treatment was associated with increased 
foot length on the affected side, possibly representing improve-
ments in heel strike and gait quality. Parents generally found MSI 
therapy to be beneficial to their children in ways that were not 
captured by the main outcome measure. We think that further 
assessment of manipulative therapies to address the muscle and 
extracellular matrix changes in spastic CP is warranted. Future 
studies might consider inclusion of other outcomes measures in 
the research design, including ones that measure quality of move-
ment, spasticity, quality of life, and functional changes in domains, 
such as mobility, self-care, communication, and social function.
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